ChemoCentryx

ChemoCentryx, Inc. (NASDAQ: CCXI) is a biopharmaceutical company founded in 1997 commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. In the United States, ChemoCentryx markets TAVNEOS? (avacopan), the first approved orally administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe Hidradenitis Suppurativa (HS) and C3 glomerulopathy (C3G). Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer. Our goal is to change treatment paradigms in orphan and rare disease—specifically targeting the chronic inflammatory pathway while avoiding immuno-suppression. TAVNEOS, our first commercial drug product, and each of our drug candidates are designed to selectively block a specific chemoattractant receptor. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives.

网站

https://www.chemocentryx.com

ChemoCentryx的外部链接

所属行业

生物技术研究

规模

51-200 人

总部

San Carlos，California

类型

上市公司

创立

1997

领域

Biopharmaceutical、autoimmune diseases、inflammatory disorders、orphan and rare diseases、ANCA-associated vasculitis、oral therapeutics、immuno-oncology、Hidradenitis Suppurativa、Chronic Kidney Disease、Diabetic Nephropathy、Pancreatic Cancer、C3 Glomerulopathy、Small Molecule Therapeutics、Chemoattractant System、Chemokine、Drug Discovery、Inflammatory Bowel Disease (IBD)、Rheumatoid Arthritis (RA)、Avacopan、Complement Receptor、ADVOCATE、AURORA、LUMINA和TAVNEOS